Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

BACKGROUND: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatm...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Subst Abuse Treat Prev Policy
Egile Nagusiak: Aas, Christer F., Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Lim, Aaron G., Johansson, Kjell Arne, Fadnes, Lars Thore
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325258/
https://ncbi.nlm.nih.gov/pubmed/32605625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13011-020-00286-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak